Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IS A RISK-ADAPTED THERAPY POSSIBLE IN CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS
Autore:
HEIDENREICH A; NEUBAUER S; MOUL JW;
Indirizzi:
UNIV COLOGNE,KLIN & POLIKLIN UROL,JOSEPH STELZMANN STR 9 D-50931 COLOGNE GERMANY
Titolo Testata:
Aktuelle Urologie
fascicolo: 3, volume: 29, anno: 1998,
pagine: 93 - 102
SICI:
0001-7868(1998)29:3<93:IARTPI>2.0.ZU;2-F
Fonte:
ISI
Lingua:
GER
Soggetto:
LYMPH-NODE DISSECTION; TESTIS CANCER; ADJUVANT CHEMOTHERAPY; EMBRYONAL CARCINOMA; PROGNOSTIC FACTORS; NUCLEAR ANTIGEN; SURVEILLANCE; ORCHIECTOMY; METASTASIS; EXPRESSION;
Keywords:
TESTIS CANCER; GERM CELL TUMOR; ONCOGENE; TUMOR SUPPRESSOR GENE; PROGNOSIS; NONSEMINOMA; CLINICAL STAGE I;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
52
Recensione:
Indirizzi per estratti:
Citazione:
A. Heidenreich et al., "IS A RISK-ADAPTED THERAPY POSSIBLE IN CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS", Aktuelle Urologie, 29(3), 1998, pp. 93-102

Abstract

Optimal management of patients with clinical stage I non-seminomatoustesticular germ cell tumors remains highly controversial, since all available therapeutic options, such as nerve-sparing retroperitoneal lymphadenectomy, primary chemotherapy and surveillance, lead to the samehigh cure rate of 98%. Since the majority of patients are diagnosed and treated at a young age, quality of life issues have assumed great importance for both the patient and the urologist. The development of reliable and reproducible prognostic risk factors to define low and high risk groups for occult retropertoneal metastatic disease may help clinicians to make more rational decisions about whether retroperitoneallymph-node dissection, primary chemotherapy or surveillance should follow initial orchiectomy. As of 1997 the most clinically useful prognostic risk factors are the percentage of embryonal carcinoma and the presence or absence of vascular invasion by tumor cells in the primary tumor. Assessment of both parameters enables the definition of low and high risk groups for metastatic disease with a more than 90% accuracy. Ongoing work with DNA cytometry, proliferation markers, oncogenes, tumor suppressor genes, proteases and cellular adhesion molecules may allow further stratification of patients as to their likelihood of developing occult metastases in the future. Currently, however, none of themolecular markers is superior to meticulous quantitative histopathologic analysis of the primary tumor, nor do they add additional prognostic information on vascular invasion and percentage of embryonal carcinoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:12:03